Suppr超能文献

心肌内自体 CD34+ 细胞治疗难治性心绞痛。

Intramyocardial, autologous CD34+ cell therapy for refractory angina.

机构信息

Division of Cardiology, Northwestern Memorial Hospital, Northwestern University, Chicago, IL 60611, USA.

出版信息

Circ Res. 2011 Aug 5;109(4):428-36. doi: 10.1161/CIRCRESAHA.111.245993. Epub 2011 Jul 7.

Abstract

RATIONALE

A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous CD34+ cells can improve myocardial perfusion and function.

OBJECTIVE

Evaluate the safety and bioactivity of intramyocardial injections of autologous CD34+ cells in patients with refractory angina who have exhausted all other treatment options.

METHODS AND RESULTS

In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 patients with refractory angina received 1 of 2 doses (1×10(5) or 5×10(5) cells/kg) of mobilized autologous CD34+ cells or an equal volume of diluent (placebo). Treatment was distributed into 10 sites of ischemic, viable myocardium with a NOGA mapping injection catheter. The primary outcome measure was weekly angina frequency 6 months after treatment. Weekly angina frequency was significantly lower in the low-dose group than in placebo-treated patients at both 6 months (6.8±1.1 versus 10.9±1.2, P=0.020) and 12 months (6.3±1.2 versus 11.0±1.2, P=0.035); measurements in the high-dose group were also lower, but not significantly. Similarly, improvement in exercise tolerance was significantly greater in low-dose patients than in placebo-treated patients (6 months: 139±151 versus 69±122 seconds, P=0.014; 12 months: 140±171 versus 58±146 seconds, P=0.017) and greater, but not significantly, in the high-dose group. During cell mobilization and collection, 4.6% of patients had cardiac enzyme elevations consistent with non-ST segment elevation myocardial infarction. Mortality at 12 months was 5.4% in the placebo-treatment group with no deaths among cell-treated patients.

CONCLUSIONS

Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (10(5) cells/kg) experienced significant improvements in angina frequency and exercise tolerance. The cell-mobilization and -collection procedures were associated with cardiac enzyme elevations, which will be addressed in future studies.

摘要

背景

越来越多的冠心病患者出现难治性心绞痛。临床前和早期临床数据表明,自体 CD34+细胞心肌内注射可以改善心肌灌注和功能。

目的

评估对已用尽其他所有治疗选择的难治性心绞痛患者进行自体 CD34+细胞心肌内注射的安全性和生物活性。

方法和结果

在这项前瞻性、双盲、随机、二期研究中(ClinicalTrials.gov 标识符:NCT00300053),167 例难治性心绞痛患者接受了 1 种剂量(1×10(5)或 5×10(5)细胞/公斤)的动员自体 CD34+细胞或等量稀释剂(安慰剂)。治疗通过 NOGA 映射注射导管分布到 10 个缺血、存活的心肌部位。主要终点是治疗后 6 个月每周心绞痛发作频率。在 6 个月(6.8±1.1 对 10.9±1.2,P=0.020)和 12 个月(6.3±1.2 对 11.0±1.2,P=0.035)时,低剂量组的每周心绞痛发作频率明显低于安慰剂组;高剂量组的测量值也较低,但无统计学意义。同样,低剂量组的运动耐量改善也明显大于安慰剂组(6 个月:139±151 对 69±122 秒,P=0.014;12 个月:140±171 对 58±146 秒,P=0.017),高剂量组也有所改善,但无统计学意义。在细胞动员和采集期间,4.6%的患者出现了非 ST 段抬高心肌梗死的心肌酶升高。安慰剂组 12 个月的死亡率为 5.4%,而细胞治疗组无死亡病例。

结论

接受自体 CD34+细胞(10(5)细胞/公斤)心肌内注射的难治性心绞痛患者心绞痛发作频率和运动耐量显著改善。细胞动员和采集程序与心肌酶升高有关,这将在未来的研究中得到解决。

相似文献

1
Intramyocardial, autologous CD34+ cell therapy for refractory angina.心肌内自体 CD34+ 细胞治疗难治性心绞痛。
Circ Res. 2011 Aug 5;109(4):428-36. doi: 10.1161/CIRCRESAHA.111.245993. Epub 2011 Jul 7.

引用本文的文献

本文引用的文献

2
Women and ischemic heart disease: evolving knowledge.女性与缺血性心脏病:不断发展的认知
J Am Coll Cardiol. 2009 Oct 20;54(17):1561-75. doi: 10.1016/j.jacc.2009.04.098.
3
Human studies of angiogenic gene therapy.血管生成基因治疗的人体研究。
Circ Res. 2009 Oct 9;105(8):724-36. doi: 10.1161/CIRCRESAHA.109.200386.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验